Claims
- 1. A method for modulating programmed cell death in a cell comprising contacting said cell with modulating amounts of ICH-3.
- 2. The method of claim 1 comprising using ICH-3 in the presence of ICE.
- 3. A method of promoting proIL1-β processing by a cell in the presence of ICE comprising contacting said cell with ICH-3 expressed under the control of a CMV promoter.
- 4. A method for stimulating synthesis of Ich-3 gene products in a cell comprising contacting said cell with stimulatory amounts of using lipopolysaccharide (LPS).
- 5. A monoclonal or polyclonal antibody that specifically binds ICH-3.
- 6. The antibody of claim 5, wherein said antibody binds to a 43 kDa or a 38 kDA fragment of the ICH-3 protein.
- 7. The antibody of claim 5, wherein said antibody binds to the p20 region of ICH-3.
- 8. The antibody of claim 7, wherein said antibody is made against the antigen having the amino acid peptide (H-TEFKHLSLRYGAKFD)8-MAP-LINKED.
- 9. A transgenic non-human animal comprising a disrupted Ich-3 gene.
- 10. The transgenic non-human animal as claimed in claim 9, wherein said animal is a mouse.
- 11. The transgenic non-human animal as claimed in claim 9, wherein said transgenic animal is resistant to septic shock.
- 12. The transgenic non-human animal as claimed in claim 9, wherein said transgenic animal is resistant to LPS treatment.
- 13. The transgenic non-human animal as claimed in claim 9, wherein said transgenic animal has severely reduced plasma levels of IL-1β and IL-1α after LPS injection.
- 14. The transgenic non-human animal as claimed in claim 9, wherein a 43 kDa and a 38 kDa protein reactive with an ICH-3 antibody, is absent or severely reduced in spleen, thymus, kidney, lung, brain and intestine, said antibody being made against the amino acid peptide TEFKHLSLRYGAKFD.
- 15. The transgenic non-human animal as claimed in claim 9, wherein said transgenic animal is a female mouse and said mouse contains significantly reduced numbers of oocyte-containing primordial follicles during neonatal development.
- 16. A transgenic non-human animal model for the study of septic shock wherein said animal comprises an animal with a disrupted Ich-3 gene.
- 17. Atransgenic non-human animal model for the study of infection wherein said animal comprises an animal with a disrupted Ich-3 gene.
- 18. The transgenic non-human animal as claimed in claim 9, wherein nucleotides encoding amino acids of ICH-3 are replaced with a sequence from an Ich-3 targeting vector.
- 19. The progeny of the transgenic non-human animal as claimed in claim 9.
- 20. A method of screening folliculogenic compounds, comprising:
(a) providing a transgenic non-human animal having a disrupted Ich-3 gene and exhibiting reduced endowment of primordial follicles; (b) administering a compound to be tested to said transgenic animal; (c) determining the effect of said compound on folliculogenesis of said animal; and (d) correlating the effect of said compound on folliculogenesis of said animal with an effect of said compound on folliculogenesis of a non-treated animal having a disrupted Ich-3 gene.
- 21. A method of screening compounds for treating sepsis or septic shock comprising:
(d) providing a transgenic non-human animal having a disrupted Ich-3 gene and exhibiting resistance to septic shock; (b) applying a sepsis or septic shock stimulus to said animal; (e) administering a compound to be tested to said transgenic animal; (f) determining the effect of said compound on the susceptibility to manifestatiation of sepsis or septic shock of said animal; and (d) correlating the effect of said compound on septic shock or sepsis of said animal with an effect of said compound on the sequelae of sepsis or septic shock in a non-treated animal having a disrupted Ich-3 gene or in a wild type animal.
- 22. A method of screening compounds for alteration in susceptibility to infection, or the sequelae of thermal injury, major trauma, or combinations thereof, comprising:
(g) providing a transgenic non-human animal having a disrupted Ich-3 gene and exhibiting resistance to septic shock; (b) applying a burn, trauma, infection, bacteremia or other infection to said animal; (h) administering a compound to be tested to said transgenic animal; (i) determining the effect of said compound on the susceptibility to manifestatiation of sepsis or septic shock of said animal; and (d) correlating the effect of said compound on the injury received by said animal with an effect of said compound on the sequelae of sepsis or septic shock in a non-treated animal having a disrupted Ich-3 gene or on a wild type animal.
- 23. A method of making a transgenic non-human animal having a disrupted Ich-3 gene, comprising:
(a) providing a DNA molecule comprising an intact Ich-3gene; (b) providing a targeting vector capable of disrupting said Ich-3 gene upon homologous recombination with said DNA molecule; (c) placing said DNA molecule comprising the intact Ich-3 gene and said targeting vector in contact under conditions where said DNA molecule and said targeting vector will undergo homologous recombination to produce a second DNA molecule comprising a disrupted Ich-3 gene; (d) introducing said second DNA molecule into ES cells; (e) injecting ES cells into blastocytes; (f) implanting said blastocytes containing the ES cells with the disrupted Ich-3 gene into the uterus of a pseudopregnant female; and (g) delivering a transgenic animal comprising a disrupted Ich-3 gene from said pseudopregnant female.
- 24. The method of making a transgenic non-human animal as claimed in claim 23, wherein said pseudopregnant female and said transgenic animal is a mouse.
- 25. A method for reducing mortality of sepsis in a wild-type animal comprising treating said animal with inhibitors of ICH-3.
- 26. A method for reducing mortality of burns and trauma in a wild-type animal comprising treating said animal with inhibitors of ICH-3.
- 27. A method of protecting against lung injury in common medical conditions comprising utilizing inhibitors of the pathways of apoptosis.
Parent Case Info
[0001] This application claims the benefit of the filing date of U.S. Provisional Application 60/023,937, filed Aug. 9, 1996 and is incorporated herein by reference.
STATEMENTS AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT
[0002] Part of the work performed during the development of this invention was supported by U.S. Government funds. The U.S. Government may have certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60023937 |
Aug 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08908436 |
Aug 1997 |
US |
Child |
09773670 |
Feb 2001 |
US |